Γ

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

1	Check this box if no longer subject to
L	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations
	may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned										
(City)	(State)	(Zip)								
(Street) WESTFIELD	NJ	07090		X Form filed by One Reporting Person Form filed by More than One Reporting Person						
1047 SEWARD	AVE.		4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line)						
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 07/26/2023	Officer (give title Other (specify below) below)						
1. Name and Addres <u>McMurdo Ma</u>			2. Issuer Name and Ticker or Trading Symbol <u>TITAN PHARMACEUTICALS INC</u> [TTNP]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner						
10b5-1(c). See In:	struction 10.									

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Transaction Code (Instr.		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)		5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership	
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(Instr. 4)
Common Stock	07/26/2023		Α		50,000(1)	A	\$ <mark>0</mark>	50,000	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of 3. Transaction 3A. Deemed 5. Number of 6. Date Exercisable and 7. Title and Amount of 8. Price of 9. Number of 10. 11. Nature Securities Underlying Derivative Conversion Execution Date, Transaction Derivative Expiration Date Derivative derivative Ownership of Indirect Date or Exercise Price of (Month/Dav/Year) Security (Instr. if anv Code (Instr. Securities (Month/Dav/Year) **Derivative Security (Instr.** Security Securities Form: Beneficial Acquired (A) or 3) (Month/Day/Year) 8) 3 and 4) (Instr. 5) Beneficially Direct (D) Ownership Derivative Disposed of (D) Owned or Indirect (I) (Instr. 4) (Instr. 4) Security (Instr. 3, 4 and Following Reported 5) Transaction(s) (Instr. 4) Amount or Date Expiration Number of Code (A) (D) Exercisable Title Shares Date Option to Common \$1.52⁽²⁾ 06/29/2023(2) 25,000 25 000 Purchase Α 25,000 08/15/2022 **\$**0 D Stock Common Stock Option to Common Purchase \$1.31⁽³⁾ 06/29/2023⁽³⁾ 100,000 09/15/2022 100,000 \$<mark>0</mark> 100,000 D Α Stock Common Stock

Explanation of Responses:

1. The shares reported in this transaction represent Unrestricted Stock Awards pursuant to the Issuer's Fourth Amended and Restated 2015 Omnibus Equity Incentive Plan that vested immediately on the date of grant.

2. The options were approved by the Issuer's Board of Directors on August 15, 2022. The options were conditioned on the approval by the Issuer's stockholders of an increase in the number of shares available for issuance under the 2015 Omnibus Equity Incentive Plan, which approval occurred on June 29, 2023. The exercise price of the options is equal to the closing price of the Issuer's common stock on August 15, 2022.

3. The options were approved by the Issuer's Board of Directors on September 15, 2022. The options were conditioned on the approval by the Issuer's stockholders of an increase in the number of shares available for issuance under the 2015 Omnibus Equity Incentive Plan, which approval occurred on June 29, 2023. The exercise price of the options is equal to the closing price of the Issuer's common stock on September 15, 2022.

<u>/s/ Matthew C. McMurdo</u> 07/28/2023

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.